Show
Sort by
-
- Journal Article
- A1
- open access
Segmental chromosomal alterations lead to a higher risk of relapse in infants with MYCN-non-amplified localised unresectable/disseminated neuroblastoma (a SIOPEN collaborative study)
-
Unequivocal delineation of clinicogenetic subgroups and development of a new model for improved outcome prediction in neuroblastoma
-
Quality assessment of genetic markers used for therapy stratification
-
Molecular cytogenetic definition of 17q translocation breakpoints in neuroblastoma.
-
Multicentre analysis of patterns of DNA gains and losses in 204 neuroblastoma tumors: How many genetic subgroups are there?
-
Comparative genomic hybridization (CGH) analysis of stage 4 neuroblastoma reveals high frequency of 11Q deletion in tumors lacking MYCN amplification.
-
Gain of chromosome arm 17q and adverse outcome in patients with neuroblastoma.